Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pixu 1 decoction
- Development stage
- Phase 1
- Lead developer
- Xiyuan Hospital
- Administration
- Oral
01
Overview
Pixu 1 decoction is a traditional Chinese medicine (TCM) formulation developed by Xiyuan Hospital Affiliated to China Academy of Chinese Medical Sciences for the treatment of functional dyspepsia. It is specifically designed for patients categorized under the 'spleen deficiency' (Pixu) syndrome in TCM. The decoction is part of a stratified treatment approach evaluated in clinical trials where different formulations (Pixu 1, 2, and 3) are assigned based on specific TCM diagnostic criteria. It is typically administered orally as a liquid extract to alleviate symptoms such as postprandial fullness, early satiation, and epigastric pain.
- Other names
- Pixu 1Pixu1Pixu-1
Beyond the preview
Go deeper on Pixu 1 decoction.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pixu 1 decoction.